Agilent Technologies reported fiscal second-quarter 2026 results (February–April 2026) with revenue of $1,835 million (+10.0%), operating income of $399 million (+33.0%), and net income of $339 million (+57.7%). GAAP diluted EPS jumped to $1.20 from $0.75 in the year-ago quarter, a 60% increase.
However, these headline numbers require important context. On a core basis (excluding currency and M&A), revenue grew just 6.3% — the gap between the reported +10.0% and core +6.3% is largely attributable to foreign exchange tailwinds. The market-facing metric, non-GAAP EPS, rose 14% to $1.49, and non-GAAP operating margin expanded 130 basis points to 26.4%. The 58% GAAP net income surge was materially boosted by a reversal in other income (reduced equity investment impairments), which accounts for roughly one-third of the headline improvement.
On March 6, Agilent announced the $950 million all-cash acquisition of Biocare, a U.S. clinical and research diagnostics solutions company, which is expected to become the next growth catalyst for its Life Sciences and Diagnostics segment.
1. Balance Sheet Analysis
1-1. Key Asset Comparison (Oct 31, 2025 → Apr 30, 2026)
| Item | Prior Period ($M) | Current Period ($M) | Change | Commentary |
|---|---|---|---|---|
| Cash & equivalents | 1,789 | 1,807 | +1.0% | Modest increase despite buybacks and dividends; liquidity preserved |
| Accounts receivable | 1,487 | 1,498 | +0.7% | Near-flat vs. revenue growth; DSO improving |
| Inventories | 1,025 | 1,089 | +6.2% | Finished goods +2.6%, parts/subassemblies +10.5%; staging for H2 shipments |
| PP&E, net | 2,023 | 2,099 | +3.8% | CapEx of $169M exceeding depreciation |
| Intangibles, net | 445 | 407 | -8.5% | Amortization running down purchased technology; no new acquisitions closed |
Total assets grew from $12.73B to $13.07B (+2.7%). The most notable balance sheet highlight is accounts receivable management: while six-month cumulative revenue rose 8.5%, receivables increased just 0.7%, indicating meaningful DSO improvement. This reflects Agilent's consistent post-pandemic emphasis on working capital discipline. The inventory build (+6.2%) appears to be forward-looking staging for second-half shipments, though with the $950M Biocare acquisition pending, the $1,807M cash balance provides limited cushion.
1-2. Debt Structure — Financial vs. Operating Liabilities
Financial debt: Commercial paper $304M (unchanged) + long-term debt $3,051M (+0.03%) = total debt $3,355M. Looking at senior notes specifically: book value $3,333M versus fair value $3,182M — trading at a 4.5% discount to par. This gap was similar at the prior period-end (Oct 31, 2025: fair value $3,191M / book $3,330M, a -4.2% discount), meaning no meaningful deterioration over six months.
The market-to-book discount on debt reflects that current market rates exceed the fixed coupon rates on Agilent's outstanding notes — not a sign of credit deterioration, but rather the cost of eventual refinancing. When Biocare financing is added (likely new debt at higher prevailing rates), the blended borrowing cost will rise. Six-month interest expense declined from $57M to $50M, but this advantage diminishes as lower-rate tranches mature.
Operating liabilities: Accounts payable $615M (+7.9%), deferred revenue $665M (+6.6%), employee compensation $387M (-12.6%). The deferred revenue increase supports a strengthening pipeline of recurring revenue from service contracts, software subscriptions, and extended warranties. Total contract liabilities (current + non-current) rose from $803M to $855M (+6.5%). Overall total liabilities actually declined from $5,986M to $5,943M, as reductions in employee compensation (-$56M) and other accrued liabilities ($406M → $298M) more than offset operating liability growth.
1-3. Equity Structure
Paid-in capital moved from $5,578M to $5,632M (+1.0%), while retained earnings surged from $1,389M to $1,692M (+21.8%) — reflecting six-month net income of $644M less dividends of $144M and $197M charged to retained earnings from share repurchases. Over six months, Agilent repurchased 1.6 million shares for $217M (approximately $136/share), with employee stock compensation issuances partially offsetting, resulting in shares outstanding declining from 283,054K to 282,218K. Debt-to-equity stands at 83% ($5,943M / $7,124M), remaining within a conservative leverage range.
2. Income Statement Analysis
2-1. Core Revenue Metrics (Q2 FY2026)
| Item | Prior Period ($M) | Current Period ($M) | Change |
|---|---|---|---|
| Revenue | 1,668 | 1,835 | +10.0% (core +6.3%) |
| Operating income | 300 | 399 | +33.0% |
| Operating margin | 18.0% | 21.7% | +3.7pp |
| Net income | 215 | 339 | +57.7% |
| Net margin | 12.9% | 18.5% | +5.6pp |
The 10% revenue growth amplifying to 33% operating income growth demonstrates significant operating leverage. However, approximately 4 percentage points of reported revenue growth came from currency tailwinds, which must be applied to all growth rate interpretations.
By segment on a reported basis: Life Sciences & Diagnostics $732M (+11.9%), Agilent CrossLab $759M (+6.5%), Applied Markets $344M (+14.3%) — all three segments grew. But core growth rates diverge sharply: +9%, +2%, and +11% respectively. The CrossLab gap (reported +6.5% vs. core +2%) is particularly noteworthy — Agilent's high-margin services, consumables, and software business barely grew on a currency-adjusted basis.
Geographically, Americas led at $764M (+12.7%) and Europe at $518M (+17.2%), while Asia-Pacific lagged at $553M (+0.9%), reflecting continued China biopharma recovery delays. The European +17.2% figure is materially inflated by euro strength, so the actual regional gap is narrower than headline numbers suggest.
Decomposing net income improvement: Pre-tax income improved $148M ($260M → $408M), of which operating income gains contributed $99M (67%), other income reversal (-$25M → +$21M) contributed $46M (31%), and interest expense reduction added $4M. While operations drove the majority, roughly one-third of the net income surge came from non-operating items (primarily reduced equity investment impairments) — explaining why non-GAAP EPS growth was "only" +14%.
2-2. Fixed vs. Variable Cost Analysis
Variable costs: Product cost of sales $567M (+5.4%) + services cost $278M (+5.3%) = $845M (+5.4%). Cost growth running at roughly half the revenue growth rate drove gross margin expansion from 51.9% to 54.0% (+2.1pp). The company did not detail the specific drivers; given the ~4pp currency contribution to revenue, it is unclear how much of the margin improvement reflects structural efficiency gains versus FX translation effects. IEEPA tariff refunds were not recognized as of April 30.
Fixed costs: R&D $126M (+12.5%), SG&A $465M (+2.4%). Amortization of purchased intangibles (embedded in cost of sales and SG&A) fell from $27M to $19M year-over-year. R&D investment held steady at ~6.9% of revenue. SG&A ratio improved from 27.2% to 25.3% (-1.9pp), with fixed cost leverage fully materializing as revenue scaled.
3. Cash Flow Analysis (Six Months Ended April 30, 2026)
| Item | Prior Period ($M) | Current Period ($M) | Change |
|---|---|---|---|
| Operating cash flow | 652 | 545 | -107 |
| Investing cash flow | (208) | (170) | +38 |
| Financing cash flow | (296) | (366) | -70 |
| FX effect | 9 | 9 | — |
| Net cash change | 157 | 18 | -139 |
| Period-end cash (incl. restricted) | 1,489 | 1,809 | +320 |
Operating cash flow declined $107M despite higher net income — a significant divergence. Key drivers: (1) cash taxes paid increased $72M ($248M → $320M); (2) other working capital changes deteriorated $281M ((-$14M) → (-$295M)); (3) inventory build widened $44M; (4) employee compensation payments increased $34M; partially offset by deferred tax shifts (-$28M → +$57M, +$85M impact). Free cash flow (operating CF $545M minus CapEx $169M) = $376M, down 14.7% from the prior-year $441M.
CapEx declined from $211M to $169M (-20%), suggesting Agilent is conserving capital expenditures ahead of the Biocare acquisition. Six-month shareholder returns totaled $361M ($217M buybacks + $144M dividends), rising to $393M including $32M in stock compensation taxes and excise taxes. At $393M vs. FCF of $376M, Agilent is returning more cash to shareholders than it generates in free cash — implying new debt issuance will likely be required to fund the $950M Biocare acquisition.
4. Key Issues for Investors
① Biocare $950M Acquisition (Announced March 6, 2026) — Agilent is acquiring BC Midco I, Inc. (Biocare), a U.S.-based clinical and research diagnostics solutions provider, in an all-cash transaction. Closing is targeted by Q3 FY2026 or year-end, subject to regulatory approvals and customary conditions. Biocare will be integrated into the Life Sciences & Diagnostics segment, where it is expected to serve as a meaningful revenue and margin driver. With cash of $1,807M and the acquisition priced at $950M, Agilent will almost certainly need new debt financing or will curtail buybacks materially — likely both.
② IEEPA Tariff Refund Contingency — On February 20, 2026, the U.S. Supreme Court invalidated certain IEEPA-based tariffs, and the U.S. Court of International Trade (CIT) ordered CBP to process refunds (subject to appeal). CBP opened an online refund portal on April 20, 2026. Agilent has filed for refunds but is treating recoveries as gain contingencies — no receivable has been recognized as of April 30, 2026. If and when recognized, this will represent a one-time earnings uplift, though the amount and timing remain undisclosed.
③ Asia-Pacific Stagnation (+0.9%) — While Americas and Europe printed double-digit growth, Asia-Pacific grew less than 1% on a reported basis. Asia-Pacific CrossLab revenue specifically declined ($249M → $248M). This directly reflects continued China biopharma demand weakness — a key risk factor for the second half and FY2027 outlooks. For US-listed instrument and life sciences companies broadly, Agilent's data reinforces that China recovery has not yet materialized as a meaningful contributor.
④ Recurring Revenue Durability — Non-instrumentation revenue (consumables, services, software) reached $1,217M (+8.9%), representing 66.3% of total revenue and serving as the core of Agilent's recession resilience. Contract liabilities grew from $803M to $855M (+6.5%). However, CrossLab's core growth of just +2% complicates the recurring revenue narrative — recurring revenue is defensive, but it is not currently a growth engine. Investors should distinguish between defensibility and growth when assessing this segment.
⑤ Tax Rate and Global Minimum Tax — Q2 effective tax rate was 16.9% (tax $69M / pre-tax $408M) versus 17.3% in the prior year. Agilent is subject to OECD Pillar Two (global minimum tax) top-up taxes. The U.S. OBBBA tax legislation (passed July 4, 2025) introduced elective immediate R&D deductibility for domestic R&D expenses starting FY2026-FY2027, but the company noted no material impact on the current quarter's effective rate or cash taxes.
5. Key Takeaways and Outlook
Company Guidance (Raised with Q2 Results)
| Period | Revenue | Core Growth | Non-GAAP EPS |
|---|---|---|---|
| FY2026 Full Year | $7.39B–$7.49B | +4.5%–6.0% | $6.00–$6.10 |
| Q3 FY2026 | $1.83B–$1.85B | +4.4%–5.9% | $1.48–$1.50 |
Notably, Q3 revenue guidance ($1.83B–$1.85B) is virtually flat versus Q2 actuals ($1.835B). Full-year core guidance of +4.5%–6.0% is below Q2's core +6.3%, signaling that management does not expect Q2 growth momentum to sustain through the second half.
Bull case: (1) GAAP operating margin reaching 21.7% (vs. 18.0% YoY), non-GAAP margin at 26.4% (+130bp); (2) clear operating leverage with SG&A ratio down 1.9pp; (3) Biocare acquisition adds a meaningful diagnostics growth vector; (4) Americas and Europe demand holding firm; (5) management's guidance raise itself is a positive signal.
Bear case / Risk factors: (1) Asia-Pacific recovery delay remains the largest near-term variable, with China biopharma capex still muted; (2) the 10.0% reported revenue growth vs. 6.3% core growth — a currency reversal flips this into a headwind; (3) Biocare financing will likely add net debt, compressing FCF yield for shareholders; (4) FCF already declined 14.7% YoY with buybacks exceeding free cash generation; (5) CrossLab core +2% suggests the company's most recurring segment has limited near-term growth momentum; (6) IEEPA tariff refund remains an unquantifiable upside (and downside if appeals reverse the ruling).
Bottom line: The 58% GAAP net income surge contains meaningful non-recurring tailwinds — about one-third came from other income reversals, not operations. Gross margin expansion of 2.1pp is a genuine positive but partially currency-driven and not fully explained by management. The real underlying story is a company delivering solid-but-not-exceptional core growth of 6.3% and 14% non-GAAP EPS growth, with guidance calibrated to those real rates — not the headline 58%.
For US life sciences investors, Agilent's results affirm two key themes: (1) academic, government, and pharma lab demand in the US and Europe remains healthy; and (2) China recovery is not yet a meaningful contributor to instrument/services demand, a dynamic that extends to the broader analytical instrumentation peer group.
Disclaimer
This report is prepared for informational purposes based on Agilent Technologies' SEC-filed Form 10-Q for the quarter ended April 30, 2026, and the company's Q2 FY2026 earnings press release (Form 8-K, Exhibit 99.1). It does not constitute investment advice or a recommendation to buy or sell any security. LineVest News is not a registered investment advisor.